Voyager Therapeutics, Inc. (VYGR) AI Stock Analysis

Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and platform technologies for neurological disorders. Its lead clinical candidate, VY-AADC, is in an open-label Phase 1 clinical trial for Parkinson's disease, utilizing adeno-associated virus gene therapy to deliver therapeutic genes directly to affected regions of the brain. The company's preclinical pipeline includes VY-SOD102 for amyotrophic lateral sclerosis, VY-HTT01 for Huntington's disease, VY-FXN01 for Friedreich's ataxia, and a Tau program targeting tauopathies and spinal muscular atrophy. Voyager collaborates with biopharmaceutical partners such as Neurocrine Biosciences, Pfizer Inc., and Novartis Pharma AG.

Voyager's annual top line has experienced wide swings. Revenue rose from $37.4M in FY2021 to $40.9M in FY2022, before climbing to $250.0M in FY2023, where operating margin reached 48.8% and net income was $132.3M. Revenue fell 68.0% to $80.0M in FY2024 and dropped 49.5% to $40.4M in FY2025. In FY2025, research and development expense was $134.7M and net income was -$119.7M. From FY2020 to FY2025, revenue contracted at a 5-year CAGR of -25.1%. For the latest quarter ended June 30, 2026, revenue fell 39.1% year-over-year, while trailing twelve-month revenue was $34.5M with an operating margin of -833.9%.

As of June 30, 2026, Voyager held $116.3M in cash and short-term investments against total debt of $32.6M, resulting in net cash of $83.8M. Total assets stood at $197.8M and shareholders' equity was $154.4M. Its liquidity metrics include a current ratio of 7.51 and a debt-to-equity ratio of 0.21. In FY2025, operating cash flow was -$132.5M and free cash flow was -$135.1M, with capital expenditures of $2.6M. Over the past five years, the company's share count increased 60.2%.

At its last close of $1.90 on October 16, 2026, Voyager had a market cap of $117.1M and an enterprise value of $93.7M. The stock trades at a forward P/E of 8.4x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 3.4x is below the peer median of 4.1x, and its EV-to-EBITDA ratio of 2.6x compares to the peer median of 12.0x. Over the past year, Voyager fell 64.4%, while the S&P 500 gained 16.8%. Over five years, the stock declined 53.7% against an 83.0% gain for the S&P 500.

All 11 analysts covering Voyager rate the stock a Strong Buy, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $14.89, which is 683.6% above the last close of $1.90. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $20.3M and EPS of -$1.70. For the next fiscal year, 10 analysts estimate revenue of $46.6M and EPS of -$1.28. Voyager beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Voyager Therapeutics, Inc. (VYGR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VYGR income statement, VYGR balance sheet, VYGR key metrics, VYGR analyst forecast, VYGR chart. See the VYGR stock overview for the latest quote and news.